Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium
Pierre‐Yves Dumas,
Sarah Bertoli,
Emilie Bérard,
Clémence Santana,
Maël Heiblig,
Thibaut Leguay,
Suzanne Tavitian,
Estelle Borgne,
Anne‐Charlotte de Grande,
Audrey Sarry,
Ziyad Acheaibi,
Laetitia Largeaud,
Morgane Sighieri,
Emilie Klein,
Emmanuelle Tavernier,
Marie‐Anne Hospital,
Martin Carré,
Gaspar Aspas Requena,
Anne Banos,
Norbert Vey,
Arnaud Pigneux,
Christian Récher,
Sylvain Garciaz British Journal of Haematology
· Wiley
· 2026-11-10
· DOI: 10.1111/bjh.70815
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay et al. Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium. // British Journal of Haematology. – 2026. – DOI: 10.1111/bjh.70815. – URL: https://onlinelibrary.wiley.com/doi/10.1111/bjh.70815?af=R
Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Estelle Borgne, Anne‐Charlotte de Grande, Audrey Sarry, Ziyad Acheaibi, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Marie‐Anne Hospital, Martin Carré, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, & Sylvain Garciaz (2026). Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium. British Journal of Haematology. https://doi.org/10.1111/bjh.70815
Pierre‐Yves Dumas, et al. “Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium.” British Journal of Haematology, 2026. doi:10.1111/bjh.70815.
@article{Dumas2026,
title = {Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium},
author = {Dumas, Pierre‐Yves and Bertoli, Sarah and Bérard, Emilie and Santana, Clémence and Heiblig, Maël and Leguay, Thibaut and Tavitian, Suzanne and Borgne, Estelle and Grande, Anne‐Charlotte de and Sarry, Audrey and Acheaibi, Ziyad and Largeaud, Laetitia and Sighieri, Morgane and Klein, Emilie and Tavernier, Emmanuelle and Hospital, Marie‐Anne and Carré, Martin and Requena, Gaspar Aspas and Banos, Anne and Vey, Norbert and Pigneux, Arnaud and Récher, Christian and Garciaz, Sylvain},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70815},
url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.70815?af=R}
}